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patients was evaluated using the “Likert Scale.” Direct
medical costs (medical visits, medication, additional tests)
were assessed from the national health insurance system
viewpoint, using public prices and French Social Se-
curity tariffs. We checked the comparability of patient 
population and performed appropriate statistical tests:
Chi-Square test for qualitative variables, and Student,
Mann-Whitney, Kolmogorov-Smirnov tests for quantita-
tive variables. RESULTS: The “homeopathic drugs”
strategy was statistically equivalent to the “psychotropic
drugs” strategy in terms of effectiveness (absolute varia-
tion of Hamilton score: 13.11 vs 13.02, absolute varia-
tion of Spielberger Ya and Yb scores: 14.85 vs 18.65 and
10.41 vs 13.28 respectively) and satisfaction (no statisti-
cal differences), for signiﬁcantly lower direct medical
costs reimbursed by the national health insurance system
(€53.46 vs €65.75). CONCLUSION: Homeopathic 
drugs could constitute a cost-effective alternative to psy-
chotropic drugs for treating anxiety disorders, and so
could provide an answer to public health and economic
problems posed by these drugs in France.
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OBJECTIVES: Anxiety disorders have been estimated to
cost $46.6 billion annually in the United States. Social
Anxiety Disorder (SAD) is among the most prevalent and
most chronic of the anxiety disorders, but there is a lack
of information on its economic impact. SSRIs have been
proven to be effective in the prevention of relapse but
further cost-effectiveness studies are required. This study
evaluated the cost-effectiveness of escitalopram in 
comparison with placebo in relapse prevention of SAD.
METHODS: The clinical study was conducted in outpa-
tients (18–80 years) with a primary diagnosis of gener-
alised SAD (DSM-IV) and an LSAS score 370. After 12
weeks of open-label treatment (10–20mg/day escitalo-
pram), responders were randomised to 24 weeks of 
escitalopram (n = 190) or placebo (n = 181) treatment,
to assess the relapse rate. In addition to clinical evalua-
tions, quality of life (SF-36) was assessed at baseline, and
at Weeks 12 and 24 of treatment. The use of medical ser-
vices and absence from work were recorded for the cal-
culation of direct and indirect costs from the perspective
of society. RESULTS: Patients treated with escitalopram
experienced a better quality of life compared to placebo-
treated patients (better scores for all the mental health-
related dimensions: social functioning, role emotional,
mental health; p < 0.05, and vitality, p < 0.10) and expe-
rienced fewer relapses. (The cumulative relapse rate at
Week 24 was 23% for the escitalopram group versus
56% for the placebo group.) Total costs were 22.5%
lower for patients treated with escitalopram compared to
placebo (€255 versus €329; difference not statistically sig-
niﬁcant at the 5% conﬁdence level). Relapse appears to
be an important cost driver. CONCLUSIONS: Thus, con-
tinuation of escitalopram treatment is effective in the pre-
vention of relapse in SAD patients. Escitalopram is more
cost-effective than placebo and the drug purchase costs
are more than offset by a decrease in total costs.
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OBJECTIVES: Social Anxiety Disorder (SAD) is a
chronic disabling psychiatric disorder. SSRIs are recog-
nized as effective ﬁrst-line treatment, but relapse rates as
high as 60% have been reported when treatment is 
discontinued. Inappropriate treatment of this condition
places signiﬁcant economic burdens upon society. The
aim of this study was to compare costs and the impact
on quality of life of relapsed SAD patients with a control
group of non-relapsed patients. METHODS: An eco-
nomic evaluation conducted alongside a double-blind,
placebo-controlled, 9-month relapse prevention clinical
study was used to compare the quality of life and costs
for relapsed and non-relapsed patients. Relapse was either
an increase of the Liebowitz Social Anxiety Scale (LSAS)
total score of at least 10 points or as judged by the clin-
ician. Quality of life assessments (SF-36) were made at
baseline, and at weeks 12 and 24 of treatment. Medical
services usage and sick leave days were calculated from
the societal perspective. RESULTS: At the end of the 
6-months, 133 patients had relapsed and 238 were still
in remission. Total costs at endpoint were higher for
relapsed patients compared to non-relapsed patients
(€337 versus €265). Sick leave was the main cost driver.
The likelihood of needing sick leave was 14% and 7%
for relapsed and non-relapsed patients, respectively (p =
0.047) with fewer days of sick leave for non-relapsed
patients. Relapsed patients had a poorer quality of life
compared to non-relapsed patients (lower scores for all
the mental health related dimensions: social functioning,
role emotional, mental health and vitality; p < 0.001).
CONCLUSIONS: Relapsed patients have a poorer
quality of life and incur higher costs. This highlights the
need for drugs that are effective in preventing relapse in
SAD patients.
